<div>
  <ul>
    <li>
      <p>
        Labcorp has been selected as the winning bidder of select assets of Invitae for a sum of USD 239 million. The transaction is expected to be closed in the third quarter of 2024 after the regulatory approval, following a court hearing currently scheduled for May 6.
      </p>
    </li>
    <li>
      <p>
        Through this transaction, Labcorp would acquire Invitae&rsquo;s assets, which would be auctioned through a voluntary bankruptcy protection process. Post-acquisition, Labcorp intends to harness Invitae's assets to scale its specialty testing in areas like oncology and rare diseases. This acquisition is expected to generate annual revenue of approximately USD 275 million&ndash;300 million for Labcorp, most of which will come from specialty testing.
      </p>
    </li>
    <li>
      <p>
        Labcorp, a subsidiary of Laboratory Corporation of America Holdings, is a life sciences healthcare company that provides services in diagnostics, drug development and manufacturing, research and analysis, drug safety testing, and clinical trials.
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://www.prnewswire.com/news-releases/labcorp-announces-winning-bid-for-select-assets-of-invitae-302126850.html">
      Press release
    </a>
  </p>
</div>


Precision Medicine

INCUMBENTS_PRESENT

<div>
 <p>Labcorp, a life sciences healthcare company, has been chosen as the winning bidder for acquiring select assets of Invitae, at a cost of USD 239 million. The transaction is set to close in the third quarter of 2024, pending regulatory approval. The approval is to be decided upon at a court hearing scheduled for May 6.</p>
 <p>Invitae's assets are being offered for sale as part of a voluntary bankruptcy protection process. Once acquired, Labcorp plans to utilize these assets to increase its specialty testing in fields such as oncology and rare diseases. It is projected that this acquisition will generate an annual revenue between USD 275-300 million for Labcorp, largely contributed by specialty testing.</p>
 <p>Labcorp, a subsidiary of the Laboratory Corporation of America Holdings, offers services in areas including diagnostics, drug development and manufacturing, research and analysis, drug safety testing, and clinical trials.</p>
</div>

Labcorp acquires Ivitae's select assets for USD 239 million

DISRUPTOR_PRESENT

PROMINENT_CATEGORY

<div>
 <ul>
  <li><p>Genetic testing and CDx tools company Invitae has launched an improved version of its Invitae-personalized cancer monitoring platform, which detects circulating tumor DNA (ctDNA) as a biomarker for solid tumor malignancies.</p></li>
  <li><p>The platform has CLIA approval and detects variants ranging from 18 to 50. It has a sensitivity of over 99% for detecting ctDNA at variant allele frequencies as low as 0.005%. This version also has a lower mass input limit and requires less cell-free DNA, allowing it to test previously rejected samples.</p></li>
 </ul>
</div>

Invitae launches improved version of its personalized cancer monitoring platform

Invitae, a genetic testing company, has obtained FDA market authorization for its Common Hereditary Cancers Panel. This in-vitro test analyzes human genomic DNA for genetic alterations in a set of targeted genes associated with an elevated risk of developing hereditary cancers. The FDA considers this test to be the first of its kind to be approved for commercial use, establishing a new regulatory classification.

FDA greenlights Invitae’s DNA test for cancer-predisposing genetic mutations

Invitae and Lumea have partnered to make it easier for clinicians to order Invitae's hereditary cancer genetic tests through the Lumea diagnostic platform. This collaboration aims to provide timely and valuable genetic insights for better cancer management.

All Updates

Labcorp acquires Ivitae's select assets for USD 239 million

Invitae launches improved version of its personalized cancer monitoring platform

FDA greenlights Invitae’s DNA test for cancer-predisposing genetic mutations

Invitae collaborates with Lumea to advance genetic test access

Invitae misses analyst consensus in Q1 2023; losses deepen

Invitae partners with Deerfield Management to advance drug discovery for rare diseases

Invitae partners with Epic to enhance genetic testing

Invitae beats analyst consensus in Q4 2022; losses narrow with revenue growth

Precision medicine startups announce preliminary earnings for 2022

Invitae beats analyst consensus in Q3 2022; losses narrow with revenue growth